Skip to main content

Table 3 Effect of tolvaptan 60 mg at baseline, during, and after systemic inhibition of NO synthesis on plasma concentration of sodium and plasma osmolality in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

From: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

Periods Baseline L-NMMA Post infusion p (GLM-within)
0–90 min 90–120 min 120–150 min 150–180 min 180–210 min
p-sodium (mmol/l)
 Placebo 139 ± 2 138 ± 2 138 ± 2 138 ± 1 137 ± 2 < 0.0001
 Tolvaptan 60 mg 141 ± 2 141 ± 2 141 ± 2 142 ± 2 141 ± 2
 p (GLM between) < 0.0001      
 p (aired t-test, between) 0.001 < 0.0001 < 0.0001 < 0.0001 < 0.0001  
p- osm (mosm/kg)
 Placebo 285 ± 5 283 ± 4 282 ± 5 283 ± 4 281 ± 4 < 0.0001
 Tolvaptan 60 mg 288 ± 5 290 ± 5 289 ± 5 290 ± 5 289 ± 5
 p (GLM between) < 0.0001      
 p (paired t-test, between) 0.024 < 0.0001 < 0.0001 < 0.0001 < 0.0001  
  1. Data are given as mean ± SD. General linear model (GLM) with repeated measurements was used for comparison within and between groups. Post-hoc Bonferoni test was used for comparison of infusion period (90–150 min) vs baseline period (0–90 min) and post infusion period (150–210 min) vs baseline period
  2. Paired t-test was performed for comparison between treatments at baseline period (0–90 min), L-NMMA period (90–150 min) and post-infusion period (150–210 min)